ArticleFrontiers in pharmacology2025

Correction: Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma.

Yan Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.